"It has always been and continues to be the Board's strong desire that Nino should continue to lead Immucor and he remains the company's CEO with the full support of the Board," Mr. Rosen continued. "The reasons for supporting him are straightforward: the company has excelled under his leadership; he has put together a strong management team; and his execution on our business plan continues to be outstanding. His results speak for themselves: in revenue, EPS and profitability, all have been phenomenal during his tenure as President and CEO, providing increased value to our shareholders. We have always considered him a person of professional and personal integrity."
In 2005, based on its independent investigation, the Immucor Board's Audit Committee concluded that the euro 13,500 payment was for services rendered at a medical conference. However, it also determined that the payment invoice for those services resulted in a technical violation of Foreign Corrupt Practices Act provisions. Immucor self-reported this violation to the SEC, cooperated fully with that investigation and settled with the SEC in 2007.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at http://www.immucor.com .
Statements contained in this press release that are not statements of
historical fact are "forward-looking statements" as that term is defined
under federal securities laws, including, without limitation,
|SOURCE Immucor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved